Infectious Disease Control

Johnson & Johnson Issues Call for Innovative Ideas to Reduce HIV Infections in Sub-Saharan Africa

NEW BRUNSWICK, N.J., Feb. 17, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) todayissued a call for innovative ideas as part of the DREAMS Innovation Challenge, which is supported by the U.S. President's Emergency Plan for AI...

2016-02-17 22:00 3034

SC Johnson Announces $15 Million Donation to Help Protect Families Around the World from Mosquito-Borne Diseases such as Zika

RACINE, Wisconsin, Feb. 17, 2016 /PRNewswire/ -- Today, given the rising global outbreak of Zika, SC Johnson announced it will donate at least$15 million over the next year to provide products to help needy families combat the mosquitoes that may carry the disease. As the world's leading manufact...

2016-02-17 04:56 2726

Expansion of Oxitec's Vector Control Solution in Brazil Attacking Source of Zika Virus and Dengue Fever after Positive Program Results

OXFORD, England and GERMANTOWN, Md., Jan. 19, 2016 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its subsidiary Oxitec and Piracicaba City Hall have expanded the 'FriendlyAedes aegypti Project' in Piracicaba, Brazil followin...

2016-01-19 20:00 2121

Regional Coalition Calls on Governments in Asia to Support Collaborative Efforts to Combat Growing Dengue Threat

SINGAPORE, Jan. 12, 2016 /PRNewswire/ -- On the heels of Asia's first dengue vaccine approval inthe Philippines, the inaugural Asian Dengue Summit opening in Bangkok on January 13 is making a rallying call to governments and health authorities inAsia to collaborate and integrate regi...

2016-01-12 11:56 2918

Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant

BEIJING, Jan. 4, 2016 /PRNewswire/ -- Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of vaccine products, today announced positive topline results from Phase I clinical trial of PIKA rabies vacci...

2016-01-04 09:00 3106

Yisheng Biopharma and the United States Army Medical Research Institute of Infectious Diseases Announce Collaboration on New Vaccine Against Ebola Virus

BEIJING, Dec. 14, 2015 /PRNewswire/ -- Yisheng Biopharma Co., Ltd.  ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of vaccine products, today announced that Yisheng US Biopharma Inc., its wholly owned research subsidiary, h...

2015-12-14 09:30 4186

BioAtla Enters Into Strategic License And Option Agreement With Pfizer For A New Class Of Antibody Therapeutics

SAN DIEGO, Dec. 8, 2015 /PRNewswire/ -- BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. (NYSE: PFE) to advance the development and...

2015-12-08 10:00 2528

NUS Scientists use Patient Derived Cancer Cell Culture to Predict Survival and Treatment Outcome

SINGAPORE, Dec. 1, 2015 /PRNewswire/ -- Scientists from the National University of Singapore (NUS) have developed a novel technique to efficiently culture clusters containing circulating tumour cells (CTCs) in 14 days. Using the technique, the team achieved a success rate of more than 60 per c...

2015-12-01 09:00 2693

Asia-Pacific Region Facing a 'Hidden Epidemic' of HIV Among Adolescents, New Report Finds

BANGKOK, Nov. 30, 2015 /PRNewswire/ -- The Asia-Pacific region is facing a 'hidden epidemic' of HIV among adolescents. There were an estimated 50,000 new HIV infections among adolescents aged 15-19 in 2014, accounting for 15 per cent of new infections. There are now around 220,000 adolescents liv...

2015-11-30 16:20 2326

Korean Authority Approved Green Cross' Four-strain Seasonal Influenza Vaccine

YONGIN, South Korea, Nov. 26, 2015 /PRNewswire/ -- Green Cross Corporation (Green Cross), a South Korean biopharmaceutical company, announced today that South Korea's Ministry of Food and Drug Safety has approved GCFLU QUADRIVALENT (Influenza Virus Vaccine) for immunisation of adults to help prevent...

2015-11-26 17:20 2668

UNICEF: Without Toilets, Childhood is Even Riskier Due to Malnutrition

SHANGHAI, Nov. 19, 2015 /PRNewswire/ -- Lack of access to toilets is endangering millions of the world's poorest children, UNICEF said today, pointing to emerging evidence of links between inadequate sanitation and malnutrition. Some 2.4 billion people globally do not have toilets and 946 m...

2015-11-19 13:10 2179

New Data Published in the New England Journal of Medicine Shows Potential of Compound to Fight RSV Infection in Adults and Children

SAN FRANCISCO, Nov. 19, 2015 /PRNewswire/ -- - ALS-008176 now being evaluated in RSV-infected infants - Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies announced that the New England Journal of Medicine (NEJM) will publish findings from a respiratory syncytial virus (RSV)...

2015-11-19 06:40 1699

CSIRO Maintains Key Patent for shRNA Gene Silencing Technology After European Opposition

CANBERRA, Australia, Nov. 17, 2015 /PRNewswire/ -- Australia's leading science agency, the Commonwealth Scientific and Industrial Research Organisation (CSIRO), has successfully defended another key patent for RNA interference (RNAi) gene silencing technology after oppositions by multiple opponen...

2015-11-17 16:00 2087

Jawaher Al Qasimi Launches "Sharjah Declaration" for NCDs

SHARJAH, United Arab Emirates, Nov. 17, 2015 /PRNewswire/ -- NCD Alliances from across the globe unite to adopt The Sharjah Declaration   Her Highness Sheikha Jawaher bint Mohammed Al Qasimi, Wife of His Highness the Ruler ofSharjah, Founder and Royal Patron of the Friends of Cancer Patients (F...

2015-11-17 00:13 2158

Longhorn Vaccines and Diagnostics LLC's PrimeSuite TB™ products included in the 2015 UNITAID Tuberculosis Diagnostics Technology and Market Landscape

BETHESDA, Md., Nov. 2, 2015 /PRNewswire/ -- Longhorn Vaccines and Diagnostics LLC announced today that its PrimeSuite TB™ products have been included in the 2015 Tuberculosis Diagnostics Technology and Market Landscape report by UNITAID, a world leader in the fight against HIV/AIDS, Tuberculosis ...

2015-11-02 23:01 2090

Ipsen and EpiVax collaborate to produce next generation botulinum toxins

PARIS and PROVIDENCE, R.I., Oct. 27, 2015 /PRNewswire/ -- Ipsen (Euronext: IPN; ADR: IPSEY) and the US company EpiVax, Inc. (EpiVax) today announced that they have completed a collaborative project that provides a novel approach for creating next generation botulinum neurotoxin (BoNT) and Targete...

2015-10-27 04:19 3328

Merck Unites With UNESCO to Build Research Capacity in Africa

GENEVA, Oct. 19, 2015 /PRNewswire/ -- Merck, a leading science and technology company, today launches in partnership with United Nations Educational, Scientific and Cultural Organization (UNESCO) the first edition of the UNESCO-Merck Africa Research Summit, to be held inGeneva, Switzerland. The ...

2015-10-19 22:46 1922

CARsgen Enters into Partnership Agreement with Shanghai Cancer Institute to Develop Novel CAR-T Technology

SHANGHAI, Sept. 29, 2015 /PRNewswire/ -- CARsgen Therapeutics, a private and venture backed company focused on the development of CAR-T-based autologous immunotherapy to treat solid tumors, today provided a business and clinical update on its immunotherapy programs.

2015-09-29 22:00 2142

EpiVax Says H7N9 Influenza Vaccine Failure due to "Stealth Pathogen"

PROVIDENCE R.I., Sept. 28, 2015 /PRNewswire/ -- Researchers at EpiVax and the University of Rhode Island explain how H7N9 influenza hides from the human immune system. H7N9 vaccine development has become a priority for public health officials due to its high rate of lethality and pandemic pot...

2015-09-28 10:15 2718

New Phase IIIb/IV Data Show Switching to Once-Daily Triumeq(R) Maintains HIV Viral Suppression

LONDON, Sept. 23, 2015 /PRNewswire/ -- ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study, an open-label study evaluating the efficacy, safety and tolerability of switching from an antiretroviral therapy (ART) to the once-daily, fixed-dose dolutegravir-based regi...

2015-09-23 20:40 2121
1 ... 36373839404142 ... 45